KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Biogen (BIIB) Research & Development (2016 - 2026)

Biogen has reported Research & Development over the past 18 years, most recently at $539.0 million for Q1 2026.

  • For Q1 2026, Research & Development rose 24.16% year-over-year to $539.0 million; the TTM value through Mar 2026 reached $1.9 billion, down 4.34%, while the annual FY2025 figure was $1.8 billion, 10.19% down from the prior year.
  • Research & Development for Q1 2026 was $539.0 million at Biogen, up from $509.4 million in the prior quarter.
  • Over five years, Research & Development peaked at $736.3 million in Q3 2023 and troughed at $75.0 million in Q4 2023.
  • A 5-year average of $499.7 million and a median of $516.2 million in 2024 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: plummeted 87.53% in 2023 and later skyrocketed 584.4% in 2024.
  • Year by year, Research & Development stood at $601.6 million in 2022, then plummeted by 87.53% to $75.0 million in 2023, then skyrocketed by 584.4% to $513.3 million in 2024, then dropped by 0.76% to $509.4 million in 2025, then rose by 5.81% to $539.0 million in 2026.
  • Business Quant data shows Research & Development for BIIB at $539.0 million in Q1 2026, $509.4 million in Q4 2025, and $436.1 million in Q3 2025.